Troy A. McEachron

Troy A. McEachron

Assistant Professor Of Research Translational Genomics
Department of Translational Genomics
1450 Biggy St. Health Sciences Campus Los Angeles

Translational Genomics Research Institute (TGen): Honorary Delegate, Society for Adolescent and Young Adult Oncology Annual Meeting, 2014

Translational Genomics Research Institute (TGen): UNCF/Merck Postdoctoral Science Research Fellowship, 2012-2014

University of North Carolina at Chapel Hill: Ruth L. Kirschstein National Research Service Award for Individual Pre-Doctoral Fellowships (F31), 2009-2011

University of North Carolina at Chapel Hill: AACR Minority Scholar in Cancer Research, 2009

University of North Carolina at Chapel Hill: Carl Storm Minority Fellowship Award, 2008

Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children's Oncology Group Sci Rep. 2020 Jul 23; 10(1):12318. . View in PubMed

Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma Oncoimmunology. 2019; 8(9):e1629779. . View in PubMed

Profiling targetable immune checkpoints in osteosarcoma Oncoimmunology. 2018; 7(12):e1475873. . View in PubMed

Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation Pediatr Blood Cancer. 2016 Apr; 63(4):727-30. . View in PubMed

Molecular Genetic Profiling of Adolescent Glassy Cell Carcinoma of the Cervix Reveals Targetable EGFR Amplification with Potential Therapeutic Implications J Adolesc Young Adult Oncol. 2016 09; 5(3):297-302. . View in PubMed

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 Nat Genet. 2014 May; 46(5):427-9. . View in PubMed

Histone H3 mutations in pediatric brain tumors Cold Spring Harb Perspect Biol. 2014 Apr 01; 6(4):a018689. . View in PubMed

An integrated approach to identifying clinically relevant targets in pediatric gliomas CNS Oncol. 2013 Jul; 2(4):303-6. . View in PubMed

PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of Fc? RI. Blood. 2012 May 31; 119(22):5285-93.. View in PubMed

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas Nat Genet. 2012 Jan 29; 44(3):251-3. . View in PubMed

Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells Blood Coagul Fibrinolysis. 2011 Oct; 22(7):576-82. . View in PubMed

Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis Blood. 2010 Dec 02; 116(23):5037-44. . View in PubMed

Tumors, ticks and tissue factor J Thromb Haemost. 2009 Nov; 7(11):1852-4. . View in PubMed

My research focuses on two separate yet complimentary areas: (1) the utilization of next generation genomic, transcriptomic, and proteomic technologies to profile recurrent and/or refractory pediatric, adolescent, and young adult (AYA) cancer patients for clinical decision making; (2) the use of functional genomics to identify and interrogate the developmental and therapeutic aspects of sarcomas that predominantly arise in the pediatric and AYA populations. My overall research interests are a reflection of my diverse training history. My training background in basic science includes the molecular dissection of autocrine and paracrine signaling mechanisms between tumor and host using in vitro and in vivo models and the characterization of genetically engineered mouse models of pediatric brain tumors. Additionally, my translational science training includes the interpretation and functional validation next generation sequencing data from recurrent/refractory pediatric cancer patients.

Over time I have gained an immense interest in rhabdomyosarcomas (RMS), desmoplastic small round cell tumors (DSRCT), Ewing sarcomas (EWS), and clear cell sarcomas (CCS). The relatively low mutation burden in numerous different types of sarcomas suggests that there are transcriptional and/or epigenetic mechanisms that drive these diseases. This is inline with recent studies suggesting that epigenetic dysregulation and altered developmental programing drive many pediatric malignancies. Moreover, the mechanisms by which sarcoma-specific oncogenic fusion genes initiate and/or sustain disease remains elusive. My laboratory is dedicated to developing new biological tools and approaches to enable a functional genomics inquiry into these mechanisms as to reveal insight into the underlying biology of these sarcomas. Additionally, we will interrogate patient derived material to better define the molecular characteristics of different sarcoma subtypes to enable more precise treatment strategies for these difficult diseases.
Powered by SC CTSI